Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘neuromodulation’

Global Neuromodulation Market 2020-2024

Posted by fidest press agency su martedì, 7 gennaio 2020

Technavio has been monitoring the global neuromodulation market since 2019 and the market is poised to grow by USD 5.2 billion during 2020-2024, progressing at a CAGR of more than 11% during the forecast period. The market is driven by technological advances. In addition, expanding indications are anticipated to boost the growth of the neuromodulation market. The market is witnessing significant technological advancements related to battery longevity and miniaturization of neuromodulation devices. Some of the technological advancements include improved device software and programming, the introduction of rechargeable batteries, and implantation techniques. These technological advancements have significantly enhanced the reliability and effectiveness of neuromodulation devices. Key vendors are introducing MRI-conditional implantable neuromodulation devices that do not get affected when patients undergo MR imaging examinations. Such technological advances are expected to drive the demand for neuromodulation devices during the forecast period. Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems

Posted by fidest press agency su giovedì, 28 novembre 2019

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that surgeons have begun implanting commercial patients with the Axonics r-SNM® System at Sanford Health facilities (“Sanford”).Sanford Health, headquartered in Sioux Falls, South Dakota, is one of the largest rural health systems in the United States, with 44 hospitals and 1,400 physicians in 26 states and nine countries. Axonics and Sanford have a formal agreement permitting commercial sale of the Axonics r-SNM System into Sanford facilities. Sanford Health in Sioux Falls was one of the sites for the Axonics ARTISAN-SNM pivotal clinical study.The implantable, long-lived, rechargeable, full-body MRI compatible Axonics r-SNM System was recently approved by the U.S. Food & Drug Administration (“FDA”) for patients suffering from overactive bladder, urinary retention and fecal incontinence. Raymond W. Cohen, CEO of Axonics, commented, “Sanford Health is one of a growing number of regional and national IDNs (integrated hospital delivery networks) and ambulatory surgery centers that have entered into agreements with Axonics since we received the first FDA approval in September. The pace at which we are signing agreements is quickening given the second FDA approval this November for all urinary indications. We are grateful for the opportunity to work with Sanford and could not be more pleased with the response to our product offering from the SNM implanting community.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »